XENTRIA

Owner

Goods & Services

Biologic, biosimilar, and pharmaceutical preparations for the treatment of bone disease; Biologic, biosimilar, and pharmaceutical preparations for use in the treatment of oncological and metabolic diseases and disorders, and complications associated therewith; Biologic, biosimilar, and pharmaceutical preparations for the treatment of diabetes; Biologic, biosimilar, and pharmaceutical preparations for treatment and prevention of autoimmune diseases and autoimmune disorders; Biologic, biosimilar, and pharmaceutical oncology preparations for the treatment of cancer; Anti-inflammatories; Biologic, biosimilar, and pharmaceutical preparations for the treatment and prevention of immune system related diseases and disorders; Biologic, biosimilar, and pharmaceutical preparations for use in dermatology; Biologic, biosimilar, and pharmaceutical preparations for use in rheumatology; Biologic, biosimilar, and pharmaceutical preparations, namely, anti-tumor necrosis factor alpha (TNF-a) receptor monoclonal antibody for the treatment and prevention of disease influenced by TNF-a production; Biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment and prevention of immune and inflammatory diseases and disorders